Elimination of Mother-to-Child Transmission HIV, Hepatitis B and Syphilis in Asia and the Pacific
Countries that have achieved EMTCT validation
![](/sites/default/files/2019-02/tha.png)
Thailand
Thailand was the first country in Asia and the Pacific region to achieve EMTCT validation for HIV. Thailand reached this important milestone in June 2016.
>> View publications and resources
>> Country Overview Slides
![](/sites/default/files/2019-02/mys.png)
Malaysia
Malaysia was the second country in Asia and the Pacific region to achieve EMTCT validation status for HIV in October 2018.
>> View publications and resources
>> Country Overview Slides
![](/sites/default/files/2019-02/mdv.png)
Maldives
>> Country Overview Slides
Maldives was the 3rd country in Asia and the Pacific region to achieve EMTCT validation status for HIV in July 2019.
>> View publications and resources>> Country Overview Slides
![](/sites/default/files/2019-02/lka.png)
Sri Lanka
Sri Lanka became the 4th country in Asia and the Pacific region to achieve EMTCT validation status for HIV, having done so in November 2019.
>> View publications and resources
>> Country Overview Slides
Country achievements at the time of EMTCT validation
Impact/Process indicator | Achievement |
Percentage of pregnant women attending antenatal care at least once (ANC1) | 98.3 % |
Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 99.6 % |
Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
Percentage of women accessing ANC who were tested for syphilis | 99.1 % |
Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 95.6 % |
Percentage of pregnant women living with positive syphilis serology who were treated adequately | 95.9 % |
Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
Impact/Process indicator | Achievement |
Percentage of pregnant women attending antenatal care at least once (ANC1) | 98% |
Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 98% |
Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
Percentage of women accessing ANC who were tested for syphilis | 100% |
Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | No case |
Percentage of pregnant women living with positive syphilis serology who were treated adequately | 100% |
Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
Impact/Process indicator | Achievement |
Percentage of pregnant women attending antenatal care at least once (ANC1) | 96.7 % |
Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 95.8 % |
Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
Percentage of women accessing ANC who were tested for syphilis | 95.8 % |
Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 97.5 % |
Percentage of pregnant women living with positive syphilis serology who were treated adequately | 100 % |
Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
Impact/Process indicator | Achievement |
Percentage of pregnant women attending antenatal care at least once (ANC1) | 96.4 % |
Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 95.9 % |
Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
Percentage of women accessing ANC who were tested for syphilis | 99.3 % |
Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 100 % |
Percentage of pregnant women living with positive syphilis serology who were treated adequately | 97.2 % |
Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
Coverage of hepatis B vaccine third dose (HepB3) among infants | na |